Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Stevanato Group S.p.A. (NYSE:STVN) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company.

Several equities research analysts recently weighed in on STVN shares. Citigroup reduced their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Wolfe Research started coverage on Stevanato Group in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 price objective for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Stevanato Group in a report on Monday, June 8th. Morgan Stanley reduced their target price on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Friday, March 6th. Finally, TD Cowen raised shares of Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th.

Stevanato Group Stock Performance

Shares of STVN opened at €16.99 on Tuesday. The company has a 50-day simple moving average of €17.20 and a two-hundred day simple moving average of €17.37. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.63 and a quick ratio of 1.11. The firm has a market capitalization of $5.14 billion, a PE ratio of 28.79, a price-to-earnings-growth ratio of 1.62 and a beta of 0.78. Stevanato Group has a one year low of €12.89 and a one year high of €28.00.

Stevanato Group (NYSE:STVN) last posted its earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm had revenue of €273.57 million for the quarter. During the same quarter last year, the business earned $0.10 EPS. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. On average, analysts anticipate that Stevanato Group will post 0.68 EPS for the current fiscal year.

Stevanato Group Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Wednesday, July 29th. Shareholders of record on Thursday, June 11th will be paid a dividend of $0.054 per share. The ex-dividend date of this dividend is Thursday, June 11th. This represents a dividend yield of 31.0%.

Institutional Trading of Stevanato Group

A number of hedge funds have recently made changes to their positions in STVN. Conestoga Capital Advisors LLC grew its stake in shares of Stevanato Group by 7.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company’s stock worth $116,762,000 after buying an additional 602,050 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Stevanato Group in the fourth quarter worth $9,269,000. Norges Bank purchased a new stake in shares of Stevanato Group in the fourth quarter worth $8,185,000. Credit Agricole S A bought a new position in shares of Stevanato Group during the third quarter valued at $9,785,000. Finally, T. Rowe Price Investment Management Inc. increased its holdings in shares of Stevanato Group by 10.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,923,632 shares of the company’s stock valued at $78,944,000 after acquiring an additional 368,792 shares in the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.